Cytokinetics, Incorporated $CYTK Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 8.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,684 shares of the biopharmaceutical company’s stock after buying an additional 2,474 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Cytokinetics were worth $1,014,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of CYTK. Hantz Financial Services Inc. lifted its position in shares of Cytokinetics by 2,872.7% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,264 shares during the last quarter. Assetmark Inc. raised its position in shares of Cytokinetics by 11,510.0% during the first quarter. Assetmark Inc. now owns 1,161 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 1,151 shares during the period. UMB Bank n.a. lifted its holdings in shares of Cytokinetics by 37.8% during the second quarter. UMB Bank n.a. now owns 1,593 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 437 shares during the last quarter. Covestor Ltd boosted its position in shares of Cytokinetics by 1,053.0% in the 1st quarter. Covestor Ltd now owns 1,914 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,748 shares during the period. Finally, US Bancorp DE increased its stake in Cytokinetics by 38.7% in the 1st quarter. US Bancorp DE now owns 2,410 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 672 shares in the last quarter.

Cytokinetics Stock Performance

Shares of CYTK opened at $65.44 on Monday. The company has a market capitalization of $8.00 billion, a PE ratio of -12.83 and a beta of 0.58. The company’s 50 day moving average price is $58.37 and its 200 day moving average price is $43.98. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $67.98.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to analyst estimates of $6.05 million. During the same period last year, the business earned ($1.36) EPS. The company’s quarterly revenue was up 318.1% on a year-over-year basis. On average, equities analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on CYTK shares. B. Riley reaffirmed a “buy” rating and set a $90.00 price objective (up from $80.00) on shares of Cytokinetics in a research note on Monday, November 10th. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a report on Monday, September 29th. Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Raymond James Financial initiated coverage on shares of Cytokinetics in a research report on Wednesday, July 30th. They set a “market perform” rating on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a report on Tuesday, September 2nd. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.86.

Insider Activity

In other Cytokinetics news, Director B Lynne Parshall sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $64.73, for a total value of $323,650.00. Following the transaction, the director owned 22,933 shares in the company, valued at $1,484,453.09. The trade was a 17.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 2,200 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $66.45, for a total value of $146,190.00. Following the sale, the executive vice president directly owned 140,610 shares of the company’s stock, valued at $9,343,534.50. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 67,358 shares of company stock valued at $3,895,365. 2.70% of the stock is currently owned by company insiders.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.